已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study

医学 伦瓦提尼 内科学 肝内胆管癌 回顾性队列研究 肿瘤科 肝细胞癌 索拉非尼
作者
Zhouyu Ning,Lin Xie,Xin Yan,Yi-Jun Hua,Weidong Shi,Jiahao Lin,Litao Xu,Zhiqiang Meng
出处
期刊:British Journal of Radiology [Wiley]
卷期号:96 (1150) 被引量:2
标识
DOI:10.1259/bjr.20230079
摘要

Objectives: Most patients with intrahepatic cholangiocarcinoma (ICC) present with locally advanced or metastatic disease. We report the combined potency of transarterial chemoembolization (TACE), lenvatinib and programmed cell death-1 (PD-1) inhibitors in patients with advanced and metastatic ICC. Methods: This retrospective study enrolled 32 patients with advanced or metastatic ICC between January 2017 and August 2021. Eligible patients had received gemcitabine-based TACE combined with lenvatinib with or without PD-1 inhibitor in any line of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Risk factors associated with OS were assessed using univariate and multivariate Cox regression analyses. Results: Eighteen patients received a combination of TACE and lenvatinib (TL group) and 14 patients received TACE and lenvatinib plus aPD-1 inhibitor (TLP group). The median follow-up time was 19.8 months (range 1.8–37.8). The median OS was 25.3 months (95% CI 18.5–32.1) and the median PFS was 7.3 months (95% CI 4.9–9.7). Partial response was achieved in 10 patients (31.3%), and stable disease in 13 (40.6 %) with disease control rate of 71.9%. The median OS was comparable in the TL and TLP groups (22.4 vs 27.3 months, respectively; hazard ratio: 1.245, 95% CI 0.4245–3.653; p = 0.687). The regression analysis revealed that, regardless of treatment group, a favorable independent prognostic factor for OS was HBV/HCV infection (HR: 0.063, 95% CI 0.009–0.463; p = 0.007). There were no treatment-related deaths and 81.3% of study participants experienced adverse events (AEs), the majority of which were of moderate severity (71.8% Grade 1–2). Conclusions: Gemcitabine-based TACE plus lenvatinib with or without aPD-1 inhibitor was well tolerated and provided promising therapeutic outcomes for patients with advanced and metastatic ICC. Advances in knowledge: Monotherapy with TACE, or Lenvatinib, or PD-1 inhibitors has shown limited efficacy over standard first-line chemotherapy in advanced and metastatic ICC. This work suggested the combined potency of these treatments and well-tolerance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
盒子发布了新的文献求助30
1秒前
aaaa完成签到,获得积分10
2秒前
牛婷发布了新的文献求助10
2秒前
李健的应助被布洛芬采纳,获得10
2秒前
阿蛋完成签到,获得积分10
5秒前
lishuang发布了新的文献求助10
6秒前
8秒前
思源的应助被monster采纳,获得10
8秒前
8秒前
雪白十三完成签到,获得积分10
9秒前
在水一方的应助被人间理想采纳,获得10
11秒前
11秒前
脑洞疼的应助被长情的雨采纳,获得10
11秒前
11秒前
weather_clear完成签到 ,获得积分10
12秒前
12秒前
13秒前
布洛芬发布了新的文献求助10
14秒前
汉堡包的应助被耳东采纳,获得10
16秒前
邱c发布了新的文献求助10
16秒前
2026221709发布了新的文献求助30
16秒前
徐豆芽完成签到,获得积分20
16秒前
huanfeng完成签到,获得积分10
17秒前
CipherSage的应助被monster采纳,获得10
18秒前
Fascinate完成签到 ,获得积分10
19秒前
Rr发布了新的文献求助10
19秒前
20秒前
22秒前
22秒前
Luvv完成签到,获得积分10
24秒前
阳光发布了新的文献求助10
25秒前
26秒前
人间理想发布了新的文献求助10
26秒前
机智的兔子完成签到,获得积分10
27秒前
27秒前
耳东发布了新的文献求助10
28秒前
29秒前
无极微光的应助被Jonathan采纳,获得20
29秒前
啦啦啦发布了新的文献求助10
29秒前
Ava的应助被JiaYouguo采纳,获得10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184536
求助须知:如何正确求助?哪些是违规求助? 9573526
关于积分的说明 21832132
捐赠科研通 7781791
什么是DOI,文献DOI怎么找? 3434376
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480989